Overview

Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

This protocol is a single-arm, three-cohort, phase II multicenter study designed to assess the safety and the efficacy of three all-oral combinations: Velcade with continuous low-dose melphalan and prednisone (VMP) or with continuous low-dose cyclophosphamide and prednisone (VCP) or Velcade with low-dose prednisone could be effective and well tolerated (VP).

Phase:

Phase 2

Details

Lead Sponsor:

European Myeloma Network
Stichting Hemato-Oncologie voor Volwassenen Nederland

Collaborators:

Fondazione EMN Italy Onlus
Fondazione Neoplasie Sangue Onlus

Treatments:

Bortezomib
Cyclophosphamide
Melphalan
Prednisone